JP2003292492A5 - - Google Patents

Download PDF

Info

Publication number
JP2003292492A5
JP2003292492A5 JP2003020506A JP2003020506A JP2003292492A5 JP 2003292492 A5 JP2003292492 A5 JP 2003292492A5 JP 2003020506 A JP2003020506 A JP 2003020506A JP 2003020506 A JP2003020506 A JP 2003020506A JP 2003292492 A5 JP2003292492 A5 JP 2003292492A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
optionally
hydrogen atom
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003020506A
Other languages
Japanese (ja)
Other versions
JP5072166B2 (en
JP2003292492A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2003020506A priority Critical patent/JP5072166B2/en
Priority claimed from JP2003020506A external-priority patent/JP5072166B2/en
Publication of JP2003292492A publication Critical patent/JP2003292492A/en
Publication of JP2003292492A5 publication Critical patent/JP2003292492A5/ja
Application granted granted Critical
Publication of JP5072166B2 publication Critical patent/JP5072166B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】式
【化1】

Figure 2003292492
〔式中、R1はC1-4アルキル、
R2は(I)(1) アミノ、(2) モノC1-4アルキルアミノ、(3) ジC1-4アルキルアミノ、(4)-NR5COR6(R5は水素原子またはC1-4アルキル、R6はC1-4アルキル、モノC1-4アルキルアミノまたはジC1-4アルキルアミノを示す)、(5)-NR7SO2R8(R7は水素原子またはC1-4アルキル、R8はC1-4アルキル、モノC1-4アルキルアミノまたはジC1-4アルキルアミノを示す)、(6)-CONR9R10(R9は水素原子、C1-4アルコキシを有していてもよいC1-4アルキルまたはC3-8シクロアルキル、R10は水素原子またはC1-4アルキルを示し、R9およびR10は一緒になって隣接する窒素原子とともに環を形成してもよい)、(7)-SO2NR11R12(R11は水素原子、C1-4アルコキシを有していてもよいC1-4アルキルまたはC3-8シクロアルキル、R12は水素原子またはC1-4アルキルを示し、R11およびR12は一緒になって隣接する窒素原子とともに環を形成してもよい)、(8)-CO2R13(R13はC1-4アルキルを示す)、(9) 水酸基、C1-4アルコキシ、C1-4アルキル-カルボニルオキシ、-NR5COR6(R5およびR6は前記と同意義を示す)、-NR7SO2R8(R7およびR8は前記と同意義を示す)、-CONR9R10(R9およびR10は前記と同意義を示す)、-SO2NR11R12(R11およびR12は前記と同意義を示す)または-CO2R13(R13は前記と同意義を示す)を有していてもよいC1-4アルコキシ、(10) 水酸基、-NR5COR6(R5およびR6は前記と同意義を示す)、-NR7SO2R8(R7およびR8は前記と同意義を示す)、-CONR9R10(R9およびR10は前記と同意義を示す)、-SO2NR11R12(R11およびR12は前記と同意義を示す)、-CO2R13(R13は前記と同意義を示す)またはC1-4アルコキシを有していてもよいC1-4アルキル、(11) ハロゲン原子、(12)水酸基および(13)ニトロ(以下、置換基A群と略記する)から選ばれる1ないし3個の置換基を有していてもよいフェニル、
(II)前記置換基A群およびオキソから選ばれる1ないし3個の置換基を有していてもよい複素環基、
(III)前記置換基A群から選ばれる1ないし3個の置換基を有していてもよいC3-8シクロアルキルまたは
(IV)(1)5ないし7員の含窒素複素環基、(2)水酸基および(3)C1-4アルコキシから選ばれる1ないし3個の置換基を有していてもよいC1-4アルキル、
R3は水素原子またはC1-4アルキル、
R4は(I)(1) C1-4アルコキシを有していてもよいC1-4アルコキシ、(2)-NR14COR15(R14は水素原子またはC1-4アルキル、R15はC1-4アルキルを示す)、(3)-NR16SO2R17(R16は水素原子またはC1-4アルキル、R17はC1-4アルキルを示す)、(4)-CONR18R19(R18は水素原子またはC1-4アルキル、R19はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R18およびR19は一緒になって隣接する窒素原子とともに環を形成してもよい)、(5)-SO2NR20R21(R20は水素原子またはC1-4アルキル、R21はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R20およびR21は一緒になって隣接する窒素原子とともに環を形成してもよい)、(6) (1')ヒドロキシ-C1-4アルキル、(2')C1-4アルコキシ-カルボニル、(3')モノC1-4アルキル-カルバモイルまたは(4')ジC1-4アルキル-カルバモイルを有していてもよい5ないし7員の含窒素複素環基、(7)C1-4アルコキシ-カルボニル、(8)カルボキシル、(9)モノC1-4アルキルアミノおよび(10)N-C1-4アルキル-N-C7-10アラルキルアミノ(以下、置換基B群と略記する)から選ばれる1ないし3個の置換基を有していてもよいC1-4アルキルまたは
(II)前記置換基B群から選ばれる1ないし3個の置換基を有していてもよいC3-8シクロアルキルを示す(但し、R2がハロゲン原子でモノ置換されたフェニルであるとき、R4はC1-4アルコキシで置換されたC1-4アルキルでない)〕で表される化合物またはその塩。
【請求項2】R1がC1-4アルキル、
R2が(I)(1) アミノ、(2) モノC1-4アルキルアミノ、(3) ジC1-4アルキルアミノ、(4)-NR5COR6(R5は水素原子またはC1-4アルキル、R6はC1-4アルキル、モノC1-4アルキルアミノまたはジC1-4アルキルアミノを示す)、(5)-NR7SO2R8(R7は水素原子またはC1-4アルキル、R8はC1-4アルキル、モノC1-4アルキルアミノまたはジC1-4アルキルアミノを示す)、(6)-CONR9R10(R9は水素原子、C1-4アルコキシを有していてもよいC1-4アルキルまたはC3-8シクロアルキル、R10は水素原子またはC1-4アルキルを示し、R9およびR10は一緒になって隣接する窒素原子とともに環を形成してもよい)、(7)-SO2NR11R12(R11は水素原子、C1-4アルコキシを有していてもよいC1-4アルキルまたはC3-8シクロアルキル、R12は水素原子またはC1-4アルキルを示し、R11およびR12は一緒になって隣接する窒素原子とともに環を形成してもよい)、(8)-CO2R13(R13はC1-4アルキルを示す)、(9)水酸基、C1-4アルコキシ、C1-4アルキル-カルボニルオキシ、-NR5COR6(R5およびR6は前記と同意義を示す)、-NR7SO2R8(R7およびR8は前記と同意義を示す)、-CONR9R10(R9およびR10は前記と同意義を示す)、-SO2NR11R12(R11およびR12は前記と同意義を示す)または-CO2R13(R13は前記と同意義を示す)を有していてもよいC1-4アルコキシ、(10) 水酸基、-NR5COR6(R5およびR6は前記と同意義を示す)、-NR7SO2R8(R7およびR8は前記と同意義を示す)、-CONR9R10(R9およびR10は前記と同意義を示す)、-SO2NR11R12(R11およびR12は前記と同意義を示す)、-CO2R13(R13は前記と同意義を示す)またはC1-4アルコキシを有していてもよいC1-4アルキル、(11) ハロゲン原子、(12)水酸基および(13)ニトロ(以下、置換基A群と略記する)から選ばれる1ないし3個の置換基を有していてもよいフェニル、
(II)前記置換基A群およびオキソから選ばれる1ないし3個の置換基を有していてもよい複素環基または
(III)前記置換基A群から選ばれる1ないし3個の置換基を有していてもよいC3-8シクロアルキル、
R3が水素原子またはC1-4アルキル、
R4が(I)(1) C1-4アルコキシを有していてもよいC1-4アルコキシ、(2)-NR14COR15(R14は水素原子またはC1-4アルキル、R15はC1-4アルキルを示す)、(3)-NR16SO2R17(R16は水素原子またはC1-4アルキル、R17はC1-4アルキルを示す)、(4)-CONR18R19(R18は水素原子またはC1-4アルキル、R19はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R18およびR19は一緒になって隣接する窒素原子とともに環を形成してもよい)、(5)-SO2NR20R21(R20は水素原子またはC1-4アルキル、R21はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R20およびR21は一緒になって隣接する窒素原子とともに環を形成してもよい)、(6) 5ないし7員の含窒素複素環基、(7)C1-4アルコキシ-カルボニル、(8)カルボキシル、(9)モノC1-4アルキルアミノおよび(10)N-C1-4アルキル-N-C7-10アラルキルアミノ(以下、置換基B'群と略記する)から選ばれる1ないし3個の置換基を有していてもよいC1-4アルキルまたは
(II)前記置換基B'群から選ばれる1ないし3個の置換基を有していてもよいC3-8シクロアルキルである請求項1記載の化合物。
【請求項3】R1がC1-4アルキル、
R2が(I)(1) アミノ、(2)-NHCOR6'(R6'はC1-4アルキルまたはモノC1-4アルキルアミノを示す)、(3)-CONR9R10(R9は水素原子、C1-4アルコキシを有していてもよいC1-4アルキルまたはC3-8シクロアルキル、R10は水素原子またはC1-4アルキルを示し、R9およびR10は一緒になって隣接する窒素原子とともに環を形成してもよい)、(4)-CO2R13(R13はC1-4アルキルを示す)、(5) 水酸基、C1-4アルコキシ、C1-4アルキル-カルボニルオキシ、-NHSO2R8'(R8'はC1-4アルキルを示す)または-CONR9R10(R9およびR10は前記と同意義を示す)を有していてもよいC1-4アルコキシ、(6)水酸基、-CONR9R10(R9およびR10は前記と同意義を示す)またはC1-4アルコキシを有していてもよいC1-4アルキル、(7)ハロゲン原子、(8)水酸基および(9)ニトロから選ばれる1ないし3個の置換基を有していてもよいフェニル、
(II)(1) -CONR9R10(R9およびR10は前記と同意義を示す)を有していてもよいC1-4アルキル、(2)C1-4アルキル-カルボニルオキシまたは-CONR9R10(R9およびR10は前記と同意義を示す)を有していてもよいC1-4アルコキシ(3)ハロゲン原子、(4)水酸基または(5)オキソを有していてもよい5ないし8員の含窒素複素環基、
(III)水酸基を有していていてもよいC3-8シクロアルキルまたは
(IV)(1)5ないし7員の含窒素複素環基、(2)水酸基および(3)C1-4アルコキシから選ばれる1ないし3個の置換基を有していてもよいC1-4アルキル、
R3が水素原子またはC1-4アルキル、
R4が(I)(1) C1-4アルコキシを有していてもよいC1-4アルコキシ、(2)-NR14COR15(R14は水素原子またはC1-4アルキル、R15はC1-4アルキルを示す)、(3)-NR16SO2R17(R16は水素原子またはC1-4アルキル、R17はC1-4アルキルを示す)、(4)-CONR18R19(R18は水素原子またはC1-4アルキル、R19はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R18およびR19は一緒になって隣接する窒素原子とともに環を形成してもよい)、(5)(1')ヒドロキシ-C1-4アルキル、(2')C1-4アルコキシ-カルボニルまたは(3')モノC1-4アルキル-カルバモイルを有していてもよい5ないし7員の含窒素複素環基、(6)C1-4アルコキシ-カルボニル、(7)カルボキシル、(8)モノC1-4アルキルアミノおよび(9)N-C1-4アルキル-N-C7-10アラルキルアミノから選ばれる1ないし3個の置換基を有していてもよいC1-4アルキルまたは
(II)C3-8シクロアルキルである請求項1記載の化合物。
【請求項4】R1がエチルである請求項1記載の化合物。
【請求項5】R2が(1) アミノ、(2)-NHCOR6'(R6'はC1-4アルキルまたはモノC1-4アルキルアミノを示す)、(3)-CONR9'R10'(R9'は水素原子、C1-4アルキルまたはC3-8シクロアルキル、R10'は水素原子またはC1-4アルキルを示し、R9'およびR10'は一緒になって隣接する窒素原子とともに環を形成してもよい)、(4)-CO2R13(R13はC1-4アルキルを示す)、(5)水酸基、C1-4アルコキシ、C1-4アルキル-カルボニルオキシまたは-CONR9'R10'(R9'およびR10'は前記と同意義を示す)を有していてもよいC1-4アルコキシ、(6)水酸基または-CONR9'R10'(R9'およびR10'は前記と同意義を示す)を有していてもよいC1-4アルキル、(7)ハロゲン原子、(8)水酸基および(9)ニトロから選ばれる1ないし3個の置換基を有していてもよいフェニルである請求項1記載の化合物。
【請求項6】R3がメチルである請求項1記載の化合物。
【請求項7】R4が(1)-NR14COR15(R14は水素原子またはC1-4アルキル、R15はC1-4アルキルを示す)、(2)-NR16SO2R17(R16は水素原子またはC1-4アルキル、R17はC1-4アルキルを示す)、(3)-CONR18R19(R18は水素原子またはC1-4アルキル、R19はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R18およびR19は一緒になって隣接する窒素原子とともに環を形成してもよい)、(4)5ないし7員の含窒素複素環基、(5)C1-4アルコキシ-カルボニル、(6)カルボキシル、(7)モノC1-4アルキルアミノおよび(8)N-C1-4アルキル-N-C7-10アラルキルアミノから選ばれる1ないし3個の置換基を有していてもよいC1-4アルキルである請求項1記載の化合物。
【請求項8】R4がC1-4アルコキシで置換されたC1-4アルキルである請求項1記載の化合物。
【請求項9】R4が2-メトキシエチルである請求項1記載の化合物。
【請求項10】R1がエチル、
R2が(1) アミノ、(2)-NHCOR6'(R6'はC1-4アルキルまたはモノC1-4アルキルアミノを示す)、(3)-CONR9'R10'(R9'は水素原子、C1-4アルキルまたはC3-8シクロアルキル、R10'は水素原子またはC1-4アルキルを示し、R9'およびR10'は一緒になって隣接する窒素原子とともに環を形成してもよい)、(4)-CO2R13(R13はC1-4アルキルを示す)、(5)水酸基、C1-4アルコキシ、C1-4アルキル-カルボニルオキシまたは-CONR9'R10'(R9'およびR10'は前記と同意義を示す)を有していてもよいC1-4アルコキシ、(6)水酸基または-CONR9'R10'(R9'およびR10'は前記と同意義を示す)を有していてもよいC1-4アルキル、(7)ハロゲン原子、(8)水酸基および(9)ニトロから選ばれる1ないし3個の置換基を有していてもよいフェニル、
R3がメチル、
R4が(1)-NR14COR15(R14は水素原子またはC1-4アルキル、R15はC1-4アルキルを示す)、(2)-NR16SO2R17(R16は水素原子またはC1-4アルキル、R17はC1-4アルキルを示す)、(3)-CONR18R19(R18は水素原子またはC1-4アルキル、R19はC1-4アルコキシを有していてもよいC1-4アルキルを示し、R18およびR19は一緒になって隣接する窒素原子とともに環を形成してもよい)、(4)5ないし7員の含窒素複素環基、(5)C1-4アルコキシ-カルボニル、(6)カルボキシル、(7)モノC1-4アルキルアミノおよび(8)N-C1-4アルキル-N-C7-10アラルキルアミノから選ばれる1ないし3個の置換基を有していてもよいC1-4アルキルである請求項1記載の化合物。
【請求項11】R1がエチル、
R2が(1) アミノ、(2)-NHCOR6'(R6'はC1-4アルキルまたはモノC1-4アルキルアミノを示す)、(3)-CONR9'R10'(R9'は水素原子、C1-4アルキルまたはC3-8シクロアルキル、R10'は水素原子またはC1-4アルキルを示し、R9'およびR10'は一緒になって隣接する窒素原子とともに環を形成してもよい)、(4)-CO2R13(R13はC1-4アルキルを示す)、(5)水酸基、C1-4アルコキシ、C1-4アルキル-カルボニルオキシまたは-CONR9'R10'(R9'およびR10'は前記と同意義を示す)を有していてもよいC1-4アルコキシ、(6)水酸基または-CONR9'R10'(R9'およびR10'は前記と同意義を示す)を有していてもよいC1-4アルキル、(7)ハロゲン原子、(8)水酸基および(9)ニトロから選ばれる1ないし3個の置換基を有していてもよいフェニル、
R3がメチル、
R4が2-メトキシエチルである請求項1記載の化合物。
【請求項12】2-[4-(1-(2,6-ジフルオロベンジル)-6-(4-{ [(エチルアミノ)カルボニル]アミノ}フェニル)-5-{ [(2-メトキシエチル)(メチル)アミノ]メチル}-2,4-ジオキソ-1,4-ジヒドロチエノ[2,3-d]ピリミジン-3(2H)-イル)フェニル]-N-メチルアセタミド、
2-[4-(1-(2,6-ジフルオロベンジル)-6-(4-{[(エチルアミノ)カルボニル]アミノ}フェニル)-5-{[(2-メトキシエチル)(メチル)アミノ]メチル}-2,4-ジオキソ-1,4-ジヒドロチエノ[2,3-d]ピリミジン-3(2H)-イル)フェノキシ]-N-エチルアセタミド、
N-{4-[1-(2,6-ジフルオロベンジル)-5-{[(2-メトキシエチル)(メチル)アミノ]メチル}-3-(4-メトキシ-3-メチルフェニル)-2,4-ジオキソ-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル]フェニル}-N'-エチルウレア、
N-{4-[1-(2,6-ジフルオロベンジル)-3-(4-フルオロフェニル)-5-({メチル[2-(2-オキソ-1-ピペリジニル)エチル]アミノ}メチル)-2,4-ジオキソ-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル]フェニル}-N'-エチルウレア、
N-{4-[1-(2,6-ジフルオロベンジル)-3-[4-(2-メトキシエトキシ)フェニル]-5-({メチル[2-(2-オキソ-1-ピペリジニル)エチル]アミノ}メチル)-2,4-ジオキソ-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル]フェニル}-N'-エチルウレア、
N-{2-[{[1-(2,6-ジフルオロベンジル)-6-(4-{[(エチルアミノ)カルボニル]アミノ}フェニル)-3-(4-フルオロフェニル)-2,4-ジオキソ-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-5-イル]メチル}(メチル)アミノ]エチル}-N-メチルスルホンアミド、
N-{2-[({1-(2,6-ジフルオロベンジル)-6-(4-{[(エチルアミノ)カルボニル]アミノ}フェニル)-3-[4-(2-メトキシエトキシ)フェニル]-2,4-ジオキソ-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-5-イル}メチル)(メチル)アミノ]エチル}-N-メチルスルホンアミド、
N-[4-(1-(2,6-ジフルオロベンジル)-5-{[[2-(2-メトキシエトキシ)エチル](メチル)アミノ]メチル}-2,4-ジオキソ-3フェニル-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル)フェニル]-N'-エチルウレア、
N-[4-(1-(2,6-ジフルオロベンジル)- 5-{[(2-メトキシエチル)(メチル)アミノ]メチル}-2,4-ジオキソ-3-フェニル-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル)フェニル]-N'-エチルウレア、
N-[4-(1-(2,6-ジフルオロベンジル)- 5-{[(2-エトキシエチル)(メチル)アミノ]メチル}-2,4-ジオキソ-3-(2-ピリジル)-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル)フェニル]-N'-エチルウレア、
N-[4-(1-(2,6-ジフルオロベンジル)- 5-{[(2-メトキシエチル)(メチル)アミノ]メチル}-2,4-ジオキソ-3-(5-メチル-2-ピリジル)-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル)フェニル]-N'-エチルウレアもしくは
N-[4-(1-(2,6-ジフルオロベンジル)- 5-{[(2-メトキシエチル)(メチル)アミノ]メチル}-2,4-ジオキソ-3-(6-メチル-2-ピリジル)-1,2,3,4-テトラヒドロチエノ[2,3-d]ピリミジン-6-イル)フェニル]-N'-エチルウレアまたはそれらの塩。
【請求項13】請求項1記載の化合物のプロドラッグ。
【請求項14】請求項1記載の化合物またはそのプロドラッグを含有してなる医薬。
【請求項15】性腺刺激ホルモン放出ホルモン拮抗剤である請求項14記載の医薬。
【請求項16】性ホルモン依存性疾患予防・治療剤である請求項14記載の医薬。
【請求項17】性ホルモン依存性ガン、性ホルモン依存性ガンの骨転移、前立腺肥大症、子宮筋腫、子宮内膜症、子宮線維腫、思春期早発症、無月経症、月経前症候群、月経困難症、多房性卵巣症候群、多嚢胞性卵巣症候群、ニキビ、禿頭症、アルツハイマー病、不妊症、過敏性腸症候群またはホルモン非依存性でLH-RH感受性である良性もしくは悪性腫瘍の予防・治療剤、生殖調節剤、避妊薬、排卵誘発剤あるいは性ホルモン依存性ガン術後再発予防剤である請求項14記載の医薬組成物。 [Claims]
(1) a compound represented by the formula:
Figure 2003292492
Wherein R 1 is C 1-4 alkyl,
R 2 is (I) (1) amino, (2) mono C 1-4 alkylamino, (3) di C 1-4 alkylamino, (4) -NR 5 COR 6 (R 5 is a hydrogen atom or C 1 -4 alkyl, R 6 represents C 1-4 alkyl, mono C 1-4 alkylamino or di C 1-4 alkylamino), (5) -NR 7 SO 2 R 8 (R 7 is a hydrogen atom or C 1-4 alkyl, R 8 represents C 1-4 alkyl, mono C 1-4 alkylamino or di C 1-4 alkylamino), (6) -CONR 9 R 10 (R 9 is a hydrogen atom, C 1 -4 alkoxy optionally having C 1-4 alkyl or C 3-8 cycloalkyl, R 10 represents a hydrogen atom or C 1-4 alkyl, and R 9 and R 10 together form an adjacent nitrogen may form a ring together with the atoms), (7) -SO 2 NR 11 R 12 (R 11 is a hydrogen atom, which may have a C 1-4 alkoxy C 1-4 alkyl or C 3-8 cycloalkyl, R 12 represents a hydrogen atom or C 1-4 alkyl, R 11 and R 12 together May form a ring together with the adjacent nitrogen atom), (8) -CO 2 R 13 (R 13 represents a C 1-4 alkyl), (9) a hydroxyl group, C 1-4 alkoxy, C 1-4 Alkyl-carbonyloxy, -NR 5 COR 6 (R 5 and R 6 have the same meaning as described above), -NR 7 SO 2 R 8 (R 7 and R 8 have the same meaning as described above), -CONR 9 R 10 (R 9 and R 10 have the same meaning as described above), —SO 2 NR 11 R 12 (R 11 and R 12 have the same meaning as described above), or —CO 2 R 13 (R 13 has the same meaning as described above) C 1-4 alkoxy optionally having the same meaning), (10) hydroxyl group, -NR 5 COR 6 (R 5 and R 6 have the same meaning as described above), -NR 7 SO 2 R 8 (R 7 and R 8 have the same meaning as described above), -CONR 9 R 10 (R 9 and R 10 have the same meaning as described above), -SO 2 NR 11 R 12 (R 11 and R 12 have the same meanings as above.) and the same meaning), - CO 2 R 13 ( R 13 is as defined above) or C 1-4 optionally C 1-4 optionally having alkoxy Alkyl, (11) a halogen atom, (12) hydroxyl group and (13) nitro (hereinafter, abbreviated as substituent group A) 1 selected from to may have three substituents phenyl,
(II) a heterocyclic group optionally having 1 to 3 substituents selected from the substituent group A and oxo,
(III) C 3-8 cycloalkyl optionally having 1 to 3 substituents selected from the substituent group A or
(IV) (1) a 5- to 7-membered nitrogen-containing heterocyclic group, (2) a hydroxyl group and (3) C 1- which may have 1 to 3 substituents selected from C 1-4 alkoxy. 4 alkyl,
R 3 is a hydrogen atom or C 1-4 alkyl,
R 4 is (I) (1) C 1-4 alkoxy optionally having C 1-4 alkoxy, (2) -NR 14 COR 15 (R 14 is a hydrogen atom or C 1-4 alkyl, R 15 Represents C 1-4 alkyl), (3) -NR 16 SO 2 R 17 (R 16 represents a hydrogen atom or C 1-4 alkyl, and R 17 represents C 1-4 alkyl), (4) -CONR 18 R 19 (R 18 represents a hydrogen atom or C 1-4 alkyl, R 19 is optionally C 1-4 alkyl optionally having C 1-4 alkoxy, R 18 and R 19 adjacent together (5) -SO 2 NR 20 R 21 (R 20 may have a hydrogen atom or C 1-4 alkyl, and R 21 may have a C 1-4 alkoxy) good C 1-4 an alkyl, R 20 and R 21 may form a ring together with the adjacent nitrogen atom together), (6) (1 ') a hydroxy -C 1-4 alkyl, (2 ') C 1-4 alkoxy - carbonyl, (3') mono C 1-4 alkyl - carbamoyl or (4 ') di-C 1-4 alkyl - Karubamo 5 which may have a le to 7-membered nitrogen-containing heterocyclic group, (7) C 1-4 alkoxy - carbonyl, (8) carboxy, (9) mono C 1-4 alkylamino and (10) NC 1-4 alkyl-NC 7-10 aralkylamino (hereinafter, abbreviated as substituent group B) may have 1 to 3 substituents selected from C 1-4 alkyl or
(II) a C 3-8 cycloalkyl optionally having 1 to 3 substituents selected from the substituent group B (provided that when R 2 is phenyl mono-substituted with a halogen atom, , R 4 is or a salt thereof C 1-4 has been not a C 1-4 alkyl substituted with an alkoxy)].
(2) R 1 is C 1-4 alkyl,
R 2 is (I) (1) amino, (2) mono C 1-4 alkylamino, (3) di C 1-4 alkylamino, (4) -NR 5 COR 6 (R 5 is a hydrogen atom or C 1 -4 alkyl, R 6 represents C 1-4 alkyl, mono C 1-4 alkylamino or di C 1-4 alkylamino), (5) -NR 7 SO 2 R 8 (R 7 is a hydrogen atom or C 1-4 alkyl, R 8 represents C 1-4 alkyl, mono C 1-4 alkylamino or di C 1-4 alkylamino), (6) -CONR 9 R 10 (R 9 is a hydrogen atom, C 1 -4 alkoxy optionally having C 1-4 alkyl or C 3-8 cycloalkyl, R 10 represents a hydrogen atom or C 1-4 alkyl, and R 9 and R 10 together form an adjacent nitrogen may form a ring together with the atoms), (7) -SO 2 NR 11 R 12 (R 11 is a hydrogen atom, which may have a C 1-4 alkoxy C 1-4 alkyl or C 3-8 cycloalkyl, R 12 represents a hydrogen atom or C 1-4 alkyl, R 11 and R 12 together May form a ring together with the adjacent nitrogen atom), (8) -CO 2 R 13 (R 13 represents a C 1-4 alkyl), (9) a hydroxyl group, C 1-4 alkoxy, C 1-4 Alkyl-carbonyloxy, -NR 5 COR 6 (R 5 and R 6 have the same meaning as described above), -NR 7 SO 2 R 8 (R 7 and R 8 have the same meaning as described above), -CONR 9 R 10 (R 9 and R 10 have the same meaning as described above), —SO 2 NR 11 R 12 (R 11 and R 12 have the same meaning as described above), or —CO 2 R 13 (R 13 has the same meaning as described above) C 1-4 alkoxy optionally having the same meaning), (10) hydroxyl group, -NR 5 COR 6 (R 5 and R 6 have the same meaning as described above), -NR 7 SO 2 R 8 (R 7 and R 8 have the same meaning as described above), -CONR 9 R 10 (R 9 and R 10 have the same meaning as described above), -SO 2 NR 11 R 12 (R 11 and R 12 have the same meanings as above.) and the same meaning), - CO 2 R 13 ( R 13 is as defined above) or C 1-4 optionally C 1-4 optionally having alkoxy Alkyl, (11) a halogen atom, (12) hydroxyl group and (13) nitro (hereinafter, abbreviated as substituent group A) 1 selected from to may have three substituents phenyl,
(II) a heterocyclic group which may have 1 to 3 substituents selected from the substituent group A and oxo or
(III) C 3-8 cycloalkyl optionally having 1 to 3 substituents selected from the aforementioned substituent group A,
R 3 is a hydrogen atom or C 1-4 alkyl,
R 4 is (I) (1) C 1-4 alkoxy optionally having C 1-4 alkoxy, (2) -NR 14 COR 15 (R 14 is a hydrogen atom or C 1-4 alkyl, R 15 Represents C 1-4 alkyl), (3) -NR 16 SO 2 R 17 (R 16 represents a hydrogen atom or C 1-4 alkyl, and R 17 represents C 1-4 alkyl), (4) -CONR 18 R 19 (R 18 represents a hydrogen atom or C 1-4 alkyl, R 19 is optionally C 1-4 alkyl optionally having C 1-4 alkoxy, R 18 and R 19 adjacent together (5) -SO 2 NR 20 R 21 (R 20 may have a hydrogen atom or C 1-4 alkyl, and R 21 may have a C 1-4 alkoxy) good C 1-4 an alkyl, R 20 and R 21 may form a ring together with the adjacent nitrogen atom together), (6) 5 to 7-membered nitrogen-containing heterocyclic group, (7) C 1-4 alkoxy-carbonyl, (8) carboxyl, (9) mono C 1-4 alkylamino and (10) NC 1-4 alkyl-NC 7-10 aralkylamino (hereinafter abbreviated as substituent B 'group) C 1-4 alkyl optionally having 1 to 3 substituents selected from
(II) The compound according to claim 1, which is C 3-8 cycloalkyl optionally having 1 to 3 substituents selected from the substituent group B ′.
(3) R 1 is C 1-4 alkyl,
R 2 is (I) (1) amino, (2) -NHCOR 6 ′ (R 6 ′ represents C 1-4 alkyl or mono C 1-4 alkylamino), (3) -CONR 9 R 10 (R 9 is a hydrogen atom, C 1-4 optionally C 1-4 alkyl optionally having alkoxy or C 3-8 cycloalkyl, R 10 represents a hydrogen atom or C 1-4 alkyl, R 9 and R 10 are May form a ring together with an adjacent nitrogen atom), (4) -CO 2 R 13 (R 13 represents C 1-4 alkyl), (5) a hydroxyl group, C 1-4 alkoxy, C 1-4 alkyl-carbonyloxy, —NHSO 2 R 8 ′ (R 8 ′ represents C 1-4 alkyl) or —CONR 9 R 10 (R 9 and R 10 have the same meaning as described above) and optionally C 1-4 alkoxy optionally, (6) hydroxy group, -CONR 9 R 10 (R 9 and R 10 is as defined above) or C 1-4 optionally C 1 may have an alkoxy -4 alkyl, (7) a halogen atom, (8) hydroxyl group and (9) 1 to 3 substituents selected from nitro Which may have phenyl,
(II) (1) -CONR 9 R 10 (R 9 and R 10 have the same meanings as described above), and optionally C 1-4 alkyl, (2) C 1-4 alkyl-carbonyloxy or Having a C 1-4 alkoxy (3) halogen atom, (4) hydroxyl group or (5) oxo which may have -CONR 9 R 10 (R 9 and R 10 have the same meanings as described above). A 5- to 8-membered nitrogen-containing heterocyclic group,
(III) C 3-8 cycloalkyl optionally having a hydroxyl group or
(IV) (1) a 5- to 7-membered nitrogen-containing heterocyclic group, (2) a hydroxyl group and (3) C 1- which may have 1 to 3 substituents selected from C 1-4 alkoxy. 4 alkyl,
R 3 is a hydrogen atom or C 1-4 alkyl,
R 4 is (I) (1) C 1-4 alkoxy optionally having C 1-4 alkoxy, (2) -NR 14 COR 15 (R 14 is a hydrogen atom or C 1-4 alkyl, R 15 Represents C 1-4 alkyl), (3) -NR 16 SO 2 R 17 (R 16 represents a hydrogen atom or C 1-4 alkyl, and R 17 represents C 1-4 alkyl), (4) -CONR 18 R 19 (R 18 represents a hydrogen atom or C 1-4 alkyl, R 19 is optionally C 1-4 alkyl optionally having C 1-4 alkoxy, R 18 and R 19 adjacent together (5) (1 ′) hydroxy-C 1-4 alkyl, (2 ′) C 1-4 alkoxy-carbonyl or (3 ′) mono C 1-4 alkyl A 5- to 7-membered nitrogen-containing heterocyclic group optionally having carbamoyl, (6) C 1-4 alkoxy-carbonyl, (7) carboxyl, (8) mono C 1-4 alkylamino and (9) NC 1-4 alkyl-NC 7-10 C optionally having 1 to 3 substituents selected from aralkylamino 1-4 alkyl or
2. The compound according to claim 1, which is (II) C 3-8 cycloalkyl.
4. The compound according to claim 1, wherein R 1 is ethyl.
Wherein R 2 is (1) amino, (2) -NHCOR 6 '( R 6' represents a C 1-4 alkyl or mono C 1-4 alkylamino), (3) -CONR 9 ' R 10 ′ (R 9 ′ represents a hydrogen atom, C 1-4 alkyl or C 3-8 cycloalkyl, R 10 ′ represents a hydrogen atom or C 1-4 alkyl, and R 9 ′ and R 10 ′ together (A ring may be formed with an adjacent nitrogen atom), (4) —CO 2 R 13 (R 13 represents C 1-4 alkyl), (5) hydroxyl group, C 1-4 alkoxy, C 1-4 C 1-4 alkoxy optionally having alkyl-carbonyloxy or —CONR 9 ′ R 10 ′ (R 9 ′ and R 10 ′ have the same meaning as described above), (6) hydroxyl group or —CONR 9 ′ R 10 ′ (R 9 ′ and R 10 ′ have the same meanings as described above), and may be selected from C 1-4 alkyl, (7) halogen atom, (8) hydroxyl group and (9) nitro The compound according to claim 1, which is phenyl optionally having 1 to 3 substituents.
6. The compound according to claim 1, wherein R 3 is methyl.
7. R 4 is (1) -NR 14 COR 15 ( R 14 is a hydrogen atom or C 1-4 alkyl, R 15 represents a C 1-4 alkyl), (2) -NR 16 SO 2 R 17 (R 16 is a hydrogen atom or C 1-4 alkyl, R 17 is a C 1-4 alkyl), (3) -CONR 18 R 19 (R 18 is a hydrogen atom or C 1-4 alkyl, R 19 is C 1-4 show good C 1-4 alkyl optionally having alkoxy, R 18 and R 19 may form a ring together with the adjacent nitrogen atom together) to (4) 5 7 Membered nitrogen-containing heterocyclic group, (5) C 1-4 alkoxy-carbonyl, (6) carboxyl, (7) mono C 1-4 alkylamino and (8) NC 1-4 alkyl-NC 7-10 aralkylamino The compound according to claim 1, which is C 1-4 alkyl optionally having 1 to 3 substituents selected from:
8. A compound of claim 1, wherein R 4 is C 1-4 alkyl substituted with C 1-4 alkoxy.
9. The compound according to claim 1, wherein R 4 is 2-methoxyethyl.
10. R 1 is ethyl,
R 2 is (1) amino, (2) -NHCOR 6 ′ (R 6 ′ represents C 1-4 alkyl or mono C 1-4 alkylamino), (3) -CONR 9 ′ R 10 ′ (R 9 ' Is a hydrogen atom, C 1-4 alkyl or C 3-8 cycloalkyl, R 10' represents a hydrogen atom or C 1-4 alkyl, and R 9 ' and R 10' are taken together with an adjacent nitrogen atom May form a ring), (4) -CO 2 R 13 (R 13 represents C 1-4 alkyl), (5) a hydroxyl group, C 1-4 alkoxy, C 1-4 alkyl-carbonyloxy or -CONR 9 ' R 10' (R 9 ' and R 10' have the same meanings as defined above), C 1-4 alkoxy, (6) hydroxyl group or -CONR 9 ' R 10' (R 9 ′ and R 10 ′ have the same meanings as defined above) may have 1 to 3 alkyl selected from (7) halogen atom, (8) hydroxyl group and (9) nitro Phenyl optionally having a substituent,
R 3 is methyl,
R 4 is (1) -NR 14 COR 15 (R 14 is a hydrogen atom or C 1-4 alkyl, R 15 is C 1-4 alkyl), (2) -NR 16 SO 2 R 17 (R 16 is Hydrogen atom or C 1-4 alkyl, R 17 represents C 1-4 alkyl), (3) -CONR 18 R 19 (R 18 is hydrogen atom or C 1-4 alkyl, R 19 is C 1-4 alkoxy) the show good C 1-4 alkyl optionally having, R 18 and R 19 may form a ring together with the adjacent nitrogen atom together), (4) 5 to 7-membered nitrogen-containing heterocyclic Ring group, (5) C 1-4 alkoxy-carbonyl, (6) carboxyl, (7) mono C 1-4 alkylamino and (8) NC 1-4 alkyl-NC 7-10 aralkylamino selected from The compound according to claim 1, which is C 1-4 alkyl optionally having three substituents.
(11) R 1 is ethyl,
R 2 is (1) amino, (2) -NHCOR 6 ′ (R 6 ′ represents C 1-4 alkyl or mono C 1-4 alkylamino), (3) -CONR 9 ′ R 10 ′ (R 9 ' Is a hydrogen atom, C 1-4 alkyl or C 3-8 cycloalkyl, R 10' represents a hydrogen atom or C 1-4 alkyl, and R 9 ' and R 10' are taken together with an adjacent nitrogen atom May form a ring), (4) -CO 2 R 13 (R 13 represents C 1-4 alkyl), (5) a hydroxyl group, C 1-4 alkoxy, C 1-4 alkyl-carbonyloxy or -CONR 9 ' R 10' (R 9 ' and R 10' have the same meanings as defined above), C 1-4 alkoxy, (6) hydroxyl group or -CONR 9 ' R 10' (R 9 ′ and R 10 ′ have the same meanings as defined above) may have 1 to 3 alkyl selected from (7) halogen atom, (8) hydroxyl group and (9) nitro Phenyl optionally having a substituent,
R 3 is methyl,
The compound according to claim 1, wherein R 4 is 2-methoxyethyl.
(12) 2- [4- (1- (2,6-difluorobenzyl) -6- (4-{[(ethylamino) carbonyl] amino} phenyl) -5-{[(2-methoxyethyl) (Methyl) amino] methyl} -2,4-dioxo-1,4-dihydrothieno [2,3-d] pyrimidin-3 (2H) -yl) phenyl] -N-methylacetamide,
2- [4- (1- (2,6-difluorobenzyl) -6- (4-{[(ethylamino) carbonyl] amino} phenyl) -5-{[(2-methoxyethyl) (methyl) amino] Methyl} -2,4-dioxo-1,4-dihydrothieno [2,3-d] pyrimidin-3 (2H) -yl) phenoxy] -N-ethylacetamide,
N- {4- [1- (2,6-difluorobenzyl) -5-{[(2-methoxyethyl) (methyl) amino] methyl} -3- (4-methoxy-3-methylphenyl) -2, 4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl] phenyl} -N'-ethylurea,
N- {4- [1- (2,6-difluorobenzyl) -3- (4-fluorophenyl) -5-({methyl [2- (2-oxo-1-piperidinyl) ethyl] amino} methyl)- 2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl] phenyl} -N′-ethylurea,
N- {4- [1- (2,6-difluorobenzyl) -3- [4- (2-methoxyethoxy) phenyl] -5-({methyl [2- (2-oxo-1-piperidinyl) ethyl] Amino} methyl) -2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl] phenyl} -N′-ethylurea,
N- {2-[{[1- (2,6-difluorobenzyl) -6- (4-{[(ethylamino) carbonyl] amino} phenyl) -3- (4-fluorophenyl) -2,4- Dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-5-yl] methyl} (methyl) amino] ethyl} -N-methylsulfonamide,
N- {2-[({1- (2,6-difluorobenzyl) -6- (4-{[(ethylamino) carbonyl] amino} phenyl) -3- [4- (2-methoxyethoxy) phenyl] -2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-5-yl} methyl) (methyl) amino] ethyl} -N-methylsulfonamide,
N- [4- (1- (2,6-difluorobenzyl) -5-{[[2- (2-methoxyethoxy) ethyl] (methyl) amino] methyl} -2,4-dioxo-3phenyl-1 , 2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl) phenyl] -N'-ethylurea,
N- [4- (1- (2,6-difluorobenzyl) -5-{[(2-methoxyethyl) (methyl) amino] methyl} -2,4-dioxo-3-phenyl-1,2,3 , 4-tetrahydrothieno [2,3-d] pyrimidin-6-yl) phenyl] -N'-ethylurea,
N- [4- (1- (2,6-difluorobenzyl) -5-{[(2-ethoxyethyl) (methyl) amino] methyl} -2,4-dioxo-3- (2-pyridyl) -1 , 2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl) phenyl] -N'-ethylurea,
N- [4- (1- (2,6-difluorobenzyl) -5-{[(2-methoxyethyl) (methyl) amino] methyl} -2,4-dioxo-3- (5-methyl-2- Pyridyl) -1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl) phenyl] -N'-ethylurea or
N- [4- (1- (2,6-difluorobenzyl) -5-{[(2-methoxyethyl) (methyl) amino] methyl} -2,4-dioxo-3- (6-methyl-2- Pyridyl) -1,2,3,4-tetrahydrothieno [2,3-d] pyrimidin-6-yl) phenyl] -N'-ethylurea or a salt thereof.
(13) a prodrug of the compound according to the above (1);
[14] A pharmaceutical comprising the compound according to [1] or a prodrug thereof.
15. The medicament according to claim 14, which is a gonadotropin releasing hormone antagonist.
16. The medicament according to claim 14, which is an agent for preventing or treating a sex hormone-dependent disease.
17. Sex hormone-dependent cancer, bone metastasis of sex hormone-dependent cancer, benign prostatic hyperplasia, uterine fibroids, endometriosis, uterine fibroids, precocious puberty, amenorrhea, premenstrual syndrome, menstruation Prevention / treatment of dysfunction, multilocular ovary syndrome, polycystic ovary syndrome, acne, baldness, Alzheimer's disease, infertility, irritable bowel syndrome, or benign or malignant tumors that are hormone-independent and LH-RH sensitive The pharmaceutical composition according to claim 14, which is an agent, a reproductive regulator, a contraceptive, an ovulation inducer, or an agent for preventing recurrence after sex hormone-dependent cancer surgery.

JP2003020506A 2002-01-30 2003-01-29 Thienopyrimidine compound, production method and use thereof Expired - Lifetime JP5072166B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003020506A JP5072166B2 (en) 2002-01-30 2003-01-29 Thienopyrimidine compound, production method and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002022034 2002-01-30
JP2002-22034 2002-01-30
JP2002022034 2002-01-30
JP2003020506A JP5072166B2 (en) 2002-01-30 2003-01-29 Thienopyrimidine compound, production method and use thereof

Publications (3)

Publication Number Publication Date
JP2003292492A JP2003292492A (en) 2003-10-15
JP2003292492A5 true JP2003292492A5 (en) 2006-01-26
JP5072166B2 JP5072166B2 (en) 2012-11-14

Family

ID=29253350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003020506A Expired - Lifetime JP5072166B2 (en) 2002-01-30 2003-01-29 Thienopyrimidine compound, production method and use thereof

Country Status (1)

Country Link
JP (1) JP5072166B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004207706B2 (en) 2003-01-29 2010-03-04 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
JP2008094846A (en) * 2003-01-29 2008-04-24 Takeda Chem Ind Ltd Thienopyrimidine compound and application thereof
JPWO2006083005A1 (en) * 2005-02-03 2008-06-26 武田薬品工業株式会社 Fused pyrimidine derivatives and uses thereof
PL3064498T3 (en) * 2013-10-30 2020-03-31 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof
CA2978223A1 (en) * 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
AR106472A1 (en) * 2015-10-26 2018-01-17 Gilead Apollo Llc ACC INHIBITORS AND USES OF THE SAME
CN113717149A (en) * 2021-09-29 2021-11-30 成都伊诺达博医药科技有限公司 Ruogeli key intermediate and preparation method thereof

Similar Documents

Publication Publication Date Title
CA2514407A1 (en) Thienopyrimidine compounds and use thereof
JP7317028B2 (en) Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
US20170266192A1 (en) Methods for improving diaphragm function
CN113474337A (en) 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer
KR101045154B1 (en) Composition and Antiviral Activity of Substituted Azaindoloxoacetic Piperazine Derivatives
RU2004106783A (en) 4-AMINO-6-Phenylpyrrolo [2, 3] Pyrimidine Derivatives
RU2013132758A (en) SUBSTITUTED N- (1H-INDAZOL-4-IL) IMIDAZOLE [1,2-a] PYRIDIN-3-CARBOXAMIDE COMPOUNDS AS TYROSINKIN III RECEPTOR TYROSINKINASE INHIBITORS
KR20160012196A (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2005529089A5 (en)
JP2006511491A5 (en)
CN105492436A (en) Substituted phenyl-2,3-benzodiazepines
JP2009507758A5 (en)
SG185690A1 (en) THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
Tamayo et al. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase
EP2646428A1 (en) Heterocyclic derivates preparation processes and medical uses thereof
EP2037924A2 (en) Bicyclic heteroaryl inhibitors of pde4
JP2003512467A5 (en)
JP2003292492A5 (en)
ES2828951T3 (en) Prodrugs of HIV reverse transcriptase inhibitors
JP2013501785A (en) Pyrimidine compounds as tuberculosis inhibitors
KR20070087607A (en) Pyrazolo-heteroaryl compounds useful to treat tnf-alpha and il-1 mediated diseases
US20130123290A1 (en) Pyrimidylaminobenzamide Derivatives for Treatment of Neurofibromatosis
JP2003512379A5 (en)
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
CN113754679B (en) Substituted pyrimidinediones and their use